Stillen (wormwood leaf extract) coated tablets 60 mg. №30 vial

Description

Stillen (wormwood leaf extract) coated tablets 60 mg. №30 vial

Composition

1 film-coated tablet contains:

active substance: 60 mg of wormwood leaf extract Artemisiae Argyi, soft (20: 1), containing 0.48-1.44 mg of eupatilin and 0.15-0.45 mg of geyseosidine, extractant ethanol 95%;

excipients: microcrystalline cellulose; lactose monohydrate; poloxamer; croscarmellose sodium; calcium silicate; talc; magnesium stearate;

coverings: Spectrablend white SM-1320, Spectrablend green SM-1321, Spectrablend transparent SM-1212, carnauba wax.

Dosage form

Film-coated tablets.

Main physical and chemical properties: coated, green and oval tablets with “SLT” embossing on one side and “DA” on the other.

Pharmacotherapeutic group

Remedies for acid-related diseases.
ATX code A02X.

Pharmacological properties

Stillen has a healing effect on the gastric mucosa in gastritis by enhancing the regenerative processes in the affected cells of the mucous membrane. The reparative properties of the drug are provided by flavonoids, which stimulate protein synthesis and improve local blood supply.
The anti-inflammatory activity of Stylene is realized through pronounced antioxidant properties, which prevent lipid peroxidation and block the formation of bioreactive forms of oxygen, inhibiting the release of leukotriene D4 caused by Helicobacter pylori in vitro, and reduce the activation of transcriptional N-transcriptional activation.
Stillen protects the gastric mucosa from the damaging effects of various ulcerogens, such as alcohol and nonsteroidal anti-inflammatory drugs (NSAIDs). Protection of the gastric mucosa from damage caused by alcohol is carried out by inhibiting the activity of xanthine oxidase and oxidative stress. Prevention of damage to the gastric mucosa with the use of NSAIDs is provided by increased release of endogenous prostaglandin E2 from peritoneal neutrophils and reduced production of prostaglandin F1ɑ. Stillen stimulates the secretion of mucus by the gastric epithelium, without affecting the basal secretion of gastric juice and the production of hydrochloric acid.

Indication

Treatment of lesions of the gastric mucosa (erosion, hemorrhage, redness, edema) in acute and chronic gastritis, including those caused by Helicobacter pylori infection.

Prevention of gastritis caused by NSAIDs.

Contraindication

Hypersensitivity to the components of the drug. Hereditary galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption.

Special security measures

Use with caution in patients with:

• thrombosis (thrombosis of cerebral vessels, myocardial infarction, thrombophlebitis, etc.);
• coagulopathy;
• severe liver, kidney, heart, lung and blood disorders;
• symptoms of drug allergy (rash, fever, itching, etc.) or with a history of drug allergy symptoms.

Use during pregnancy or breastfeeding

Pregnancy
Contraindicated (increases uterine tone).
Breast-feeding
It is not known whether the drug gets into breast milk. Therefore, it should not be used by women who are breast-feeding.
Ability to influence the speed of reaction when driving a car or other machinery.
No studies on the effects on the ability to drive and use machines have been performed.

Method of application and dosage

Stillen is administered orally 20-30 minutes before meals 1 tablet 3 times a day.
The maximum single dose is 1 tablet. The maximum daily dose is 3 tablets. The duration of treatment is 2-4 weeks.

Children

Due to the lack of experience in children, Stillen should not be prescribed to patients under 18 years of age.

Overdose

No cases of overdose have been studied with the use of tablets.

Side effects:

• From the gastrointestinal tract: sometimes observed nausea, anorexia, diarrhea, vomiting, heartburn and pain in the upper abdomen.
• From the nervous system: sometimes there were dizziness and headache.
• From the skin and subcutaneous tissue: sometimes there was a rash and itching.
• From the hepatobiliary system: sometimes there was an increase in ALT.
• There is a report of facial edema, although a causal relationship with the drug Stylene has not been established.